Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | HRH2 | P25021 | 12/20 | 0.42 |
| ▸ | HRH1 | P35367 | 12/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244049 | 0.85 | HRH3 (0.42) | HRH3SLC6A4HRH2HRH1 | |
| SCHEMBL7661257 | 0.82 | HRH3 (0.42) | HRH3SLC6A4GRIN1GRIN2BHRH2 | |
| SCHEMBL7243589 | 0.81 | HRH3 (0.42) | HRH3SLC6A4GRIN1GRIN2BHRH2 | |
| SCHEMBL7622894 | 0.80 | SLC6A4 (0.42) | HRH3SLC6A4GRIN1GRIN2B | |
| SCHEMBL7248335 | 0.77 | HRH3 (0.39) | HRH3SLC6A4GRIN1GRIN2BHRH2 | |
| SCHEMBL7618611 | 0.76 | HRH3 (0.39) | HRH3SLC6A4GRIN1GRIN2BHRH2 | |
| SCHEMBL6984370 | 0.76 | HRH3 (0.44) | HRH3SLC6A4GRIN1GRIN2BHRH2 | |
| SCHEMBL7250583 | 0.76 | HRH3 (0.55) | HRH3HRH2HRH1 | |
| SCHEMBL5965649 | 0.75 | HRH3 (0.42) | HRH3SLC6A4GRIN1GRIN2BHRH2 | |
| SCHEMBL5965461 | 0.75 | HRH3 (0.42) | HRH3SLC6A4GRIN1GRIN2BHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1244631-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001047893-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | HRH3 742/4885SLC6A4 4858/4885GRIN1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.